Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study

Korol, A.; Zadorozhnyy, O.; Науменко, В.; Kustryn, Taras; Pasyechnikova, N.

doi:10.2147/opth.s117791

Cited by 10 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pece and Milani reported mean 10.6-letter visual gains at the end of 1-year follow-up using intravitreal aflibercept for mCNV 19 . Korol and coauthors demonstrated 16% of the eyes had an improvement in BCVA of 3 lines or more using 1 + PRN aflibercept monotherapy in one year 18 . The patients underwent average 2.6 injections within a year.…”

Section: Discussionmentioning

confidence: 99%

“…There were 50.0% of patients having at least 15-letter increase following our aflibercept monotherapy, equal to 50.0% in the MYRROR report 16 . We used mean 2.11 aflibercept injections during one-year period, similar or less than mean 2.6 or 4.2 injections in the two preceding researches 16 , 18 . Most of the intravitreal aflibercept were administered in the first 3 months, similar to the report from the MYRROR study 16 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Wang

Huang

Chang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV). The patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to February 2013, while from March 2013 to July 2016 patients were treated by 1 + PRN intravitreal aflibercept, all with monthly follow-up for 12 months. Primary outcome measures included change in central foveal thickness (CFT) in 1 mm by spectral-domain optic coherence tomography, and best corrected visual acuity (BCVA) at month 12. Complications after injections were recorded. The intra-group changes in CFT and BCVA were compared with Wilcoxon signed rank test, the between-group difference compared with Wilcoxon rank sum test. Fisher’s exact test was used for categorical comparison between groups. Seventy-eight eyes of 78 patients were collected. There were 42 eyes in bevacizumab group, with mean age of 53.2 ± 5.4 years and 27 female patients of them. The mean BCVA significantly improved from baseline 0.56 ± 0.35 logMAR to 0.35 ± 0.35 logMAR at Month 12 after bevacizumab treatment (p < 0.001). The mean CFT significantly decreased from baseline 315.3 ± 25.6 μm to 253.7 ± 24.4 μm at Month 12 following intravitreal bevacizumab (p < 0.001). There were 36 eyes in aflibercept group, with mean age of 52.8 ± 6.8 years and 24 female patients of them. The mean BCVA significantly improved from baseline 0.61 ± 0.47 logMAR to 0.38 ± 0.41 logMAR at Month 12 after aflibercept treatment (p < 0.001). The mean CFT significantly decreased from baseline 328.2 ± 19.8 μm to 241.8 ± 27.2 μm at Month 12 following intravitreal aflibercept (p < 0.001). The baseline demographics, lens status, axial length, refractive errors, duration of symptoms, BCVA, and CFT did not differ significantly between groups (p > 0.05). There was no significant difference between bevacizumab and aflibercept groups in BCVA and CFT from Month 1 to Month 12 (p > 0.05). Injection number of aflibercept was 2.11 ± 0.41, less than that of bevacizumab (3.23 ± 0.38) during 12-month period (p = 0.01). There were no systemic thromboembolic event, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis following injections in both groups. We concluded that both aflibercept and bevacizumab can effectively treat choroidal neovascularization in high myopes. Intravitreal aflibercept had similar efficacy but less treatment number than bevacizumab for mCNV during 12-month period.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Wang

Huang

Chang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, our study adds the comparison between the three different anti-VEGF outcomes in terms of visual gains and mean number of injections per year in a larger cohort of patients with myopic CNV. Two prospective studies looking at aflibercept treatment for myopic CNV include those by Pece and Milani 22 and Korol et al 23 In the former, 33 eyes were studied, with a PRN based treatment provided after an initial injection. Similar to the retrospective study by Bruè et al, a significant improvement in BCVA was observed (mean improvement of 10.6 letters) which was greater in those under 50, and those who commenced with a lower baseline BCVA (⩽75 letters).…”

Section: Discussionmentioning

confidence: 99%

“…Data on anatomical changes observed by OCT may also be considered and is expected to correlate with the improvement in BCVA. [21][22][23] Long-term real-world data providing an insight into BCVA improvements that can be expected will provide valuable information for both clinicians and patients, by giving a realistic suggestion of what treatment may achieve. Further studies adding to the limited pool of data on long-term outcomes in clinical settings remain an important avenue of research.…”

Section: Discussionmentioning

confidence: 99%

Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization

Corazza

Kabbani

Soomro

et al. 2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To describe real world data in patients affected by myopic choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factors (VEGFs) and to compare our results with previous studies and clinical trials. Methods: This retrospective monocentric cohort study analyzed 96 eyes of 96 myopic-CNV patients treated with an anti-VEGF pro-re-nata regimen over a 3-year-long follow up period. Aflibercept and Ranibizumab were considered as first-line agents whereas Bevacizumab was reserved on a compassionate basis in patients outside the criteria for treatment. All patients underwent a best-corrected visual acuity (BCVA) recording at each follow up visit. Results: Our data showed that all three molecules produced significant improvements in BCVA at year 1, with no significant differences between the three drugs. Moreover, during the second year of treatment, Ranibizumab and Bevacizumab showed a significant improvement in the visual function. However, at year 3 of treatment, the data available indicated the BCVA improvement was not significant with Ranibizumab and Bevacizumab. In addition, no significant difference in the average number of injections between the three groups was detected over the follow up period. No serious adverse events were recorded, but five minor adverse events documented. Conclusion: Our study correlates with previous studies showing significant BCVA gains with the use of these molecules. Similarly, all three molecules seem to provide a similar duration of effects as previous studies have shown, with a low ocular adverse event rate.

show abstract

“…Visual acuity improved from 0.2 at baseline to 0.35 at month 12 and retina thickness decreased from 285 µm at baseline to 227 µm at month 12. 21…”

Section: Discussionmentioning

confidence: 99%

Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization

Howaidy

Eldaly

2019

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To compare visual functional improvement and retinal structural changes of aflibercept versus ranibizumab for the management of treatment-naïve choroidal neovascularization related to pathological myopia. Patients and methods: A prospective randomized study included patients suffering from myopic choroidal neovascularization. Patients received three intravitreal injections of aflibercept (2 mg) or ranibizumab (0.5 mg) in 1:1 ratio every 4 weeks. Ophthalmic evaluation and optical coherence tomography were performed at baseline, 1, 2, and 3 months after last injection. Primary outcome measure was the visual acuity change from baseline to month 3 after injection. Secondary outcome measures included change in retinal thickness and the relation of morphological and functional changes to baseline assessment parameters. Results: A total of 48 myopic patients (48 eyes) suffering from myopic choroidal neovascularization were randomly assigned to receive either aflibercept (Group A) or ranibizumab (Group B). In Group A, best-corrected visual acuity significantly improved from 0.53 ± 0.10 logMAR to 0.38 ± 0.11 logMAR, at 3 months, and from 0.55 ± 0.11 logMAR to 0.39 ± 0.12 logMAR in Group B. Whereas, retinal thickness reduced from 317.7 ± 53.6 µm to 164.5 ± 81.9 µm in Group A, and from 321.1 ± 98.8 µm at baseline to 178.9 ± 64.5 µm in Group B at month 3. Changes in best-corrected visual acuity and central macular thickness were statistically insignificant between the two groups at final visit. Conclusion: Both aflibercept and ranibizumab provided a significant improvement in visual acuity and retinal thickness in patients with myopic choroidal neovascularization. Comparable functional and architectural results were achieved by both treatment modalities.

show abstract

Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study

Cited by 10 publications

References 33 publications

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization

Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization

Contact Info

Product

Resources

About